Indaptus Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3 COLUMBUS CIRCLE, NEW YORK, NY, 10019
Mailing Address
3 COLUMBUS CIRCLE, NEW YORK, NY, 10019
Phone
(646) 427-2727
Fiscal Year End
1231
EIN
863158720
Financial Overview
FY2025
$9.31M
Total Assets
$-21.58
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D Beneficial ownership report (>5%) | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 10-K Annual financial report | March 17, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | March 2, 2026 | View on SEC |
| 3 Initial insider ownership report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 3 Initial insider ownership report | February 26, 2026 | View on SEC |
Material Events
8-K
Leadership Change
March 24, 2026
High Impact
- New investor group led by Yun Yao secures 96.4% voting control
- Complete board reconstitution and leadership overhaul
8-K
Strategy Change
February 27, 2026
High Impact
- David E. Lazar gains controlling interest, signaling a dramatic strategic pivot.
- Company shifts focus from drug development to acquiring an 'operating business' that generates revenue and profit.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.